Skip to content

Abstract B110: Effector CD4 T cells convert transient responses to KRAS targeted therapy into long-term durable remissions in pancreatic cancer

Sep 2026 · Cancer Research · 0 citations

TL;DR

IL-21-elicited CD4 T cells exert anti-tumor activity in mice, and potentially in humans, which can convert transient responses to KRAS inhibition into durable remissions in pancreatic cancer.

Abstract

Pancreatic ductal adenocarcinoma is refractory to most therapies, including immunotherapies, where reinvigoration of CD8 T cells with immune checkpoint blockade is insufficient to induce long-term durable remissions. Direct inhibitors of KRAS are clinically promising, although acquired resistance is common. To test if immunotherapy can synergize with KRAS inhibition to achieve long-term durable remission, we modeled KRAS inhibitor (KRASi) response and relapse in mice by using poorly immunogenetic orthotopically implanted PDAC mouse models. Unlike chemotherapy or checkpoint blockade combinations, a computationally designed IL-21 cytokine mimic (21h10) developed in collaboration with David Baker’s lab leads to long-term durable remissions. These durable remissions were observed across multiple mouse models , in combination with multiple KRAS inhibitors (MRTX1133, daraxonrasib, adagrasib), and in tumors with acquired resistance to KRAS inhibition via YAP amplification. Neither CD8 T cells nor MHC class I expression on tumor cells were important for efficacy of KRAS inhibition and 21h10 immunotherapy. Instead cDC2-primed CD4 T cells producing IFNg were crucial. Single cell analysis of the tumor microenvironment revealed that 21h10 along with KRAS inhibitors induced dramatic expansion of Th1-polarized CD4 T cells, and we used Tbx21-/- mice lacking Th1 cells and Ifng-/- mice to confirm a requirement for IFNg-producing CD4 T cells . CD4 T cells do not kill tumor cells directly, as cancer cell lacking MHCII expression preserved complete response to the treatment. Phagocytic macrophages were induced both in vivo and in vitro in the presence of 21h10 and Th1-polarized CD4 T cells, suggesting that macrophages are orchestrated to phagocytose cancer cells. To determine whether 21h10 might have a similar mechanism of action in humans, we analyzed ex vivo culture of 21h10 with human PDAC infiltrating T cells by single cell transcriptional profiling and showed a strong induction of IFNG production and other genes related to T cell activation and loss of Tregs. Thus IL-21-elicited CD4 T cells exert anti-tumor activity in mice, and potentially in humans, which can convert transient responses to KRAS inhibition into durable remissions. Li Qiang, Megan Hoffman, Jung-Ho Chun, Brendan Parent, Felix Hambitzer, Frank Peprah, Courtney Kureshi, Birkley Lim, Eugena Chang, Michael Walsh, Julissa Tello, Tavus Atajanova, Hojeong Shin, Corey Perkins, Rakeeb Kureshi, Yaniris Molina-Aponte, James Dougan, Chong Zuo, Lauren Brais, Thomas Clancy, James Cleary, Jason Hornick, Brandon Huffman, Joseph Mancias, George Molina, Mark Fairweather, Jonathan Nowak, Kimberly Perez, Douglas Rubinson, Sarah Slater, Ritchell van Dams, Jiping Wang, Brian Wolpin, Kwok-kin Wong, Harshabad Singh, Andrew Aguirre, David Baker, Michael Dougan, Stephanie Dougan. Effector CD4 T cells convert transient responses to KRAS targeted therapy into long-term durable remissions in pancreatic cancer [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B110.

View source

Similar papers

Open access Sep 2026

CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...

Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al. · 0 citations
Sep 2026

Abstract B054: Combined RAS Inhibition and Immune Checkpoint Blockade Overcome NF-κB-Mediated Immune Evasion in Chemoresistant Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Surgery is the only potentially curative treatment, yet approximately 85% of patients present with unresectable disease. For these patients, chemotherapy remains the standard treatment, though nearly all develop resistance and diseas...

K. Gulay, A. Martsinkovskiy, A. Lowy et al. · 0 citations
Sep 2026

Abstract B108: CXCR4 inhibition reprograms immune checkpoint networks and enhances anti-tumor immunity in patient-derived pancreatic cancer organoid–PBMC co-cultures

A patient-specific ex vivo organoid model is developed to define CXCL12/CXCR4-mediated immune regulation and identify additional cellular and molecular targets to enhance antitumor efficacy and demonstrate that CXCR4 inhibition enhances immune-cell infiltration and activation, modulates checkpoint expression, and promo...

I. Pellicciotta, G. Manji, A. Raufi et al. · 0 citations
Sep 2026

Abstract B053: RAS(ON) inhibition, but not chemotherapy, sensitizes RAS mutant PDAC to immunotherapy via tumor microenvironment remodeling in preclinical models

Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immune checkpoint blockade and combining anti-PD-(L)1 therapy with standard-of-care chemotherapy has not improved clinical outcomes over chemotherapy alone. Because oncogenic RAS drives both tumor growth and tumor-intrinsic immune suppression, we h...

L. Grigoryan, Keith Macaraig, Victor Batiste et al. · 0 citations
Sep 2026

Abstract B119: Generation of an Endogenous PDAC-Specific TCR Transgenic Mouse

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignancies and remains largely refractory to chemotherapy and immunotherapy. Although KRAS inhibitors show promising initial efficacy, resistance rapidly emerges, and immunotherapy responses are mostly restricted to the rare subset of patients with micr...

Chong Zuo, Li Qiang, Madeline Fitzgibbon et al. · 0 citations
Sep 2026

Abstract PR010: A mutant KRAS-targeted peptide vaccine in combination with RAS(ON) multi-selective inhibition and immune checkpoint modulators enhances anti-tumor immunity in preclinical PDAC models

Recent clinical advances using RAS-targeted small-molecule inhibitors, including daraxonrasib, a RAS(ON) multi-selective, noncovalent, tri-complex inhibitor, has shown promising responses but are limited in durability for pancreatic ductal adenocarcinoma (PDAC). Preclinical studies indicate that RAS inhibition ca...

Zi-Rui Zhu, Benjamin C. Barrett, Aadi Bhattacharya et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.